While many analysts predict the worldwide pharmaceutical market could reach $3 trillion by 2020, the pharmaceutical industry can achieve such growth only if it brings many fundamentally new drugs to market. This challenge requires a remedy for the current pharmaceutical productivity crisis that is greatly slowing the process of identifying novel drug targets and propelling the related therapeutics to market. The pharmaceutical industry is increasingly regarding genomics-based drug discovery as a potential solution to this problem.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

The number of independent genomics companies has been rapidly increasing, along with the potential capability and applicability of their technology. The potential of genomics research to yield successful pharmaceuticals is reflected by the increasing number of genomics-dedicated companies, in-house pharmaceutical companies' initiatives, mergers, acquisitions, and partnerships.

Through an extensive review of the resources available from the industry, we have identified 106 public or private companies that are essentially focused on genomics or proteomics.

In this report, we profile ten genomics companies in depth-Celera Genomics, Incyte Genomics, Human Genome Sciences, Millennium Pharmaceuticals, Lexicon Genetics, Medigene, GPC Biotech, DeCODE Genetics, Pharmagene, and Galapagos Genomics. These companies offer a cross-sectional overview of the genomics sector in terms of corporate size, business concept, and geographic location. In addition to comments on the business concepts, all corporate profiles contain annotated lists of collaborations, intellectual property, and development pipeline elements (when applicable).

Outlook and Opportunity for Genomics-Based Therapeutics: An Analysis of Key Competitor Pipelines is currently available for $4,250.

Decision Resources, Inc. is a world leader in research publications, multi client advisory services, and customized consulting to the pharmaceutical and biotechnology industries. Each year, more than 1,000 health care organizations, including the top biotech and pharmaceutical companies, turn to Decision Resources to shape strategy, develop insight, allocate resources, and drive growth in their chosen markets. Visit Decision Resources at http://www.dresources.com/

Contact Tim Daley, 781.296.2636 (phone); 781.296.2550 (fax); tdaley@dresources.com.

In Europe, contact Francoise Bidart, +32.2.351.4082 (phone); +32.2.351.2347 (fax); fbidart@decisionresources.be.

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (phone); +81.3.5401.2617 (fax); makiko@bl.mmtr.or.jp.


NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Tim Daley of Decision Resources, Inc., +1-781-296-2636,

Pfizer, Schering-Plough, and Bristol-Myers Squibb Prepare to Vie for HIV Antifungal Market Leadership when Pfizer's Diflucan Patent Expires

View Now